Pulmonary sarcoidosis in an HIV/human T-cell lymphotrophic viruses I/II coinfected patient.

J Natl Med Assoc

Division of Infectious Disease, Howard University College of Medicine, 2041 Georgia Ave NW, Washington, DC 20059, USA.

Published: December 2010

Coexistence of HIV, pulmonary sarcoidosis, and human T-cell lymphotrophic viruses (HTLV) I/II has not been well reported and studied. Although the exact etiology of sarcoidosis is unknown, immunologic abnormalities have been the focus of human immunodeficiency virus (HIV)-related sarcoidosis and it is thought to be a manifestation of immune reconstitution inflammatory syndrome. We report the case of an African American woman with HIV and HTLV I/II coinfection who developed pulmonary sarcoidosis several months after the initiation of antiretroviral therapy. Despite the fact that most common etiologies of pulmonary nodules in HIV patients include mycobacterial and fungal infections, sarcoidosis should be considered in differential diagnosis. This disease may continuously rise due to the increasing number of people who are receiving antiretroviral therapy, leading to an improved immune system.

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0027-9684(15)30754-9DOI Listing

Publication Analysis

Top Keywords

pulmonary sarcoidosis
12
t-cell lymphotrophic
8
lymphotrophic viruses
8
htlv i/ii
8
antiretroviral therapy
8
sarcoidosis
5
pulmonary
4
sarcoidosis hiv/human
4
hiv/human t-cell
4
viruses i/ii
4

Similar Publications

Purpose: The priorities and concerns of sarcoidosis patients in the United States (US) have not been well-described.

Methods: A survey constructed by sarcoidosis patients and doctors was administered to US sarcoidosis patients. The survey queried patients concerning their demographics, disease state, disease impact on health and well-being, health care priorities and impressions of sarcoidosis care.

View Article and Find Full Text PDF

Background: We compared long-term clinical outcomes between patients with cardiac sarcoidosis (CS) who received no treatment (NT), steroid treatment (ST), disease-modifying anti-rheumatic drugs (DMARDs), or tumor necrosis factor alpha inhibitors (TNF).

Methods: Patients from SSM healthcare system's data warehouse were identified using ICD codes. Inclusion criteria included at least 6 months of follow-up.

View Article and Find Full Text PDF

Sarcoidosis is considered a T-helper (Th) 1 related disease, but a transition from Th1 to Th2 pathway activation has been postulated in sarcoidosis-associated pulmonary fibrosis (SAPF). Fraction of exhaled nitric oxide (FENO) is a marker of Th2 airway inflammation, but alveolar concentration of nitric oxide (CANO) can be measured to assess Th2 inflammation in the periphery of the lung. The aim of this study is to assess whether CANO can be considered a biomarker of SAPF or active pulmonary sarcoidosis.

View Article and Find Full Text PDF

Novel Sarcoidosis Epitope Augments MHCII, CD80/CD86 Expression, Promotes B-Cell Differentiation and IgG Production.

Am J Respir Cell Mol Biol

January 2025

Wayne State University, Division of Pulmonary, Critical Care and Sleep Medicine, Detroit, Michigan, United States;

Numerous chronic human disorders are associated with immune activation by obscure antigen(s). We identified a novel sarcoidosis-epitope (ChainA) by immunoscreening of a novel T7 phage library and confirmed an abundance of ChainA IgG-antibody in sarcoidosis. We tested whether ChainA epitope elicits immune responses through B-cell activation, plasma cell differentiation and antibody production.

View Article and Find Full Text PDF

Jiawei Yanghe Decoction alleviates pulmonary sarcoidosis by upregulating NR1D1/2 and suppressing Th17 cells.

J Ethnopharmacol

January 2025

Institute of Respiratory Diseases, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China. Electronic address:

Ethnopharmacological Relevance: Jiawei Yanghe Decoction (JWYHD) is a modified version traditional Chinese medicine formula Yanghe Decoction which has been used to treat various autoimmune diseases. However, the effect of JWYHD on pulmonary sarcoidosis remains unclear.

Aim Of The Study: This study aimed to determine the therapeutic efficacy and potential mechanism of action of JWYHD in pulmonary sarcoidosis.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!